Industry News
-
Kamau Reports First Multi-Patient Data for a Sickle Cell Therapy That Corrects the Mutation Itself
Nov 04 2026 -
Ultragenyx to Cut About 20% of Staff and Drop Its Wilson Disease Gene Therapy
Nov 03 2026 -
UK Expands Casgevy to Younger Sickle Cell and Beta-Thalassemia Patients
Nov 03 2026 -
uniQure’s AMT-130 AAV Gene Therapy for Huntington’s Disease Wins FDA Priority Review, Decision Due May 2027
Nov 02 2026 -
Gene Editing Gains Momentum at ESGCT 2026 in Hamburg
Nov 01 2026 -
Aspen Neuroscience Prices a $141M IPO for Its iPSC Parkinson’s Cell Therapy
Oct 29 2026 -
Novartis Stands By Its $12B Avidity Bet Despite a $1.9B Impairment on a Muscular Dystrophy Candidate
Oct 27 2026 -
FDA Draft Guidance Would Streamline Approvals of Individualized Gene-Editing Therapies
Oct 27 2026 -
Plowshare Therapies Advances an AAV Gene Therapy for Maple Syrup Urine Disease, with a Calf as Proof of Concept
Oct 27 2026